Clinical Trials in Nashville

Showing 4301-4320 of 20,298 trials

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

NCT07142252

This Phase 2 study is a 2-arm, multi-center, double-masked, placebo-controlled, 2:1 randomized sequential trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleukin/placebo once every 14 days over 26 weeks with an additional 6-month follow-up period.

Type 1 Diabetes Mellitus

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)66 participantsStarted Nov 2025

Nashville, Tennessee, United States

Active Not RecruitingPhase 3< 1 mile

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

NCT03690388

The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.

Differentiated Thyroid Cancer

Exelixis187 participantsStarted Oct 2018

Newport Beach, California, United States • Sacramento, California, United States • San Francisco, California, United States +161 more locations

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Find Trials by Condition in Nashville

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

Home-Based Cardiac Rehabilitation for Patients With Heart Failure

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants

Single-Sided Deafness and Asymmetric Hearing Loss

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors